Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tissue Repair Cells · 1 trial · 1 indication
The primary objective of this study is to determine whether the placement of Tissue Repair Cells (TRCs) at the time of tooth extraction can safely and effectively promote bone regeneration in alveolar bone defects created by tooth extraction. * Safety was assessed through adverse event reporting * Bone regeneration was assessed through measures of bone mineral density and bone volume fraction of biopsied regenerated bone tissue. Bone regeneration was also measured through radiographic analysis of relative bone height gain (% of the bone height regenerated relative to the height before tooth extraction)
| Arm | Type | Description |
|---|---|---|
| Tissue Repair Cells (TRC) | EXPERIMENTAL | Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier |
| Control | SHAM_COMPARATOR | Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy. |
| Name | Type | Description |
|---|---|---|
| Tissue Repair Cells (TRC) | BIOLOGICAL | 30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket. |
| Control | DEVICE | Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction |
Inclusion Criteria: * Age range: 20 to 70 years * Gender: Male and female * Patients must be able and willing to follow study procedures and instructions * Patients must have read, understood and signed an informed consent form * Patients must require tooth extraction as a result of caries, periodo...
Tissue Repair Cells is an investigational cell therapy being studied for the treatment of alveolar bone loss, a condition involving the deterioration of the bone that supports the teeth. It is in Phase 1 clinical development for this musculoskeletal indication.
Tissue Repair Cells is being developed by Vericel Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol VCEL. The therapy is currently in Phase 1 clinical development for alveolar bone loss.
Tissue Repair Cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. One Phase 1 trial for alveolar bone loss has been completed, and the therapy remains in early-stage clinical investigation.
Tissue Repair Cells has been studied in one clinical trial, NCT00755911, titled "Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy." This Phase 1, sham-controlled, randomized study enrolled 24 participants with alveolar bone loss in the United States and has been completed.
Yes, Tissue Repair Cells is the same therapy that was studied under the name Aastrom Biosciences Autologous Tissue Repair Cell Therapy in clinical trial NCT00755911. The trial evaluated the treatment of alveolar bone defects using this autologous cell therapy.